| Volume: | 100 |
|---|---|
| Day's Low: | NA |
| 52-wk Low: | $32.22 |
| Previous Close: | $44.11 |
| Dividend: | $1.71 |
| Market Cap: | 63,871,300 |
| Avg Volume: | 1,619,900 |
|---|---|
| Day's High: | NA |
| 52-wk High: | $50.70 |
| Open Price: | NA |
| Yield: | 7.75% |
| P/E (Forward): | 7.34 |
| 7:56 AM | 3/19/2010 | EU Panel Backs Marketing Authorization For Nivestim |
| 3:27 PM | 3/18/2010 | UPDATE: Jury Rules For AstraZeneca In Seroquel Injury Trial |
| 10:58 AM | 3/18/2010 | NJ Jury Rules For AstraZeneca In First Seroquel Injury Trial |
| 6:34 AM | 3/18/2010 | UPDATE: Vectura Falls As Novartis Hands Over VR315 In US |
| 6:34 PM | 3/16/2010 | UPDATE:Sen Kohl Probes Price Differences In Drugs In US, Abroad |
| 5:37 PM | 3/16/2010 | Sen Kohl Probes Price Differences In Drugs Sold In US, Abroad |
| 12:56 PM | 3/16/2010 | Emerging Markets To Make Half Of Pharma Sales Growth By '13 -Study |
| 3/22/2010 | Futures Fall; Drug Stocks in Focus (WSJ.com) |
| 3/22/2010 | U.S. stock futures point to weaker start (MarketWatch.com) |
| 3/18/2010 | Corporate Watch (WSJ.com) |
| 3/18/2010 | Jury Rules for Astra in Seroquel Trial (WSJ.com) |
| 3/18/2010 | FDA Looks to Streamline Rules for New Drug Cocktails (WSJ.com) |
| 3/18/2010 | FDA Is Easing Way for Drug Cocktails (WSJ.com) |
| 3/17/2010 | AstraZeneca Eyes Emerging Markets (WSJ.com) |
| 3/16/2010 | AstraZeneca Maps 'Selective' Expansion in Emerging Markets (WSJ.com) |
| Most Recent Quarter ($) | Same Quarter Last Year ($) | % Change | |
| EPS, Pro Forma | 1.46 | NA | NA |
| EPS, GAAP | 1.07 | 0.87 | 22.99 |
| Consensus Estimate | 1.36 | NA | NA |
| Trailing 12 Months | Year-Earlier Period | % Change | |
| EPS, Pro Forma | NA | 4.20 | NA |
| EPS, GAAP | 5.19 | 4.20 | 23.57 |
| Consensus Estimate | NA | NA | NA |
| AZN | Industry Average | |
| P/E (TTM) | 8.50 | 13.10 |
| P/E (Forward) | 7.34 | 13.30 |
| PEG Ratio | 1.04 | 1.56 |
| Price/Sales | 1.95 | 2.64 |
| Beta | 0.66 | 0.71 |